VJHemOnc is committed to improving our service to you

iwCLL 2019 | iFCG for first-line treatment of IGHV-mutated CLL

VJHemOnc is committed to improving our service to you

Nitin Jain

Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) in patients with previously untreated chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Dr Jain explains the key differences between the iFCG and the standard FCR regimens, and reveals a high rate of undetectable MRD with the iFCG regimen. This interview took place at the 18th International Workshop on CLL (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter